Recent Updates
Recently added Catalysts

BMS-986326

Phase 1

Dermatitis, Atopic | Small molecule | Dermatology |Bristol-Myers Squibb Company|Last Updated: May 26, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment64

FDA Designations

No designations recorded

Clinical trial landscape

BMS-986326 · 3 trials · 3 indications

Phase 1 3
NCT06248814A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic DermatitisDermatitis, Atopic
COMPLETED64 Analytics
NCT06013995A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of LupusLupus
COMPLETED45 Analytics
NCT04736134A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy ParticipantsHealthy Participants
COMPLETED88 Analytics
PHASE1COMPLETED
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis
Dermatitis, Atopic
NCT0624881464
Unlock trial analytics
PHASE1COMPLETED
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus
Lupus
NCT0601399545
Unlock trial analytics
PHASE1COMPLETED
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants
Healthy Participants
NCT0473613488
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of participants with adverse events (AEs)
Up to approximately 224 days
Number of participants with serious adverse events (SAEs)
Up to approximately 224 days
Number of participants with clinical laboratory abnormalities
Up to approximately 224 days
Number of participants with vital sign abnormalities
Up to approximately 224 days
Number of participants with electrocardiogram (ECG) abnormalities
Up to approximately 224 days
Number of participants with physical examination abnormalities
Up to approximately 224 days
Number of participants with physical examinations abnormalities
Up to 175 days

Secondary Endpoints

Maximum observed concentration (Cmax)
Up to approximately 224 days
Time of maximum observed concentration (Tmax)
Up to approximately 224 days
Area under the concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]
Up to approximately 224 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelCROSSOVER
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Placebo, followed by BMS-986326 Dose A or Dose BEXPERIMENTAL -
BMS-986326 Dose A, followed by PlaceboEXPERIMENTAL -
BMS-986326 Dose B, followed by PlaceboEXPERIMENTAL -
Cohort A: BMS-986326 Dose 1 IVEXPERIMENTAL -
Cohort B: BMS-986326 Dose 2 IVEXPERIMENTAL -
Cohort C1: BMS-986326 Dose 3 IVEXPERIMENTAL -
Cohort C2: BMS-986326 Dose 3 SCEXPERIMENTAL -
Cohort D2: BMS-986326 Dose 4 SCEXPERIMENTAL -
Cohort E2: BMS-986326 Dose 3 SCEXPERIMENTAL -
Active Treatment (BMS 986326) IVEXPERIMENTALIntravenous (IV)
Active Treatment (BMS 986326) SCEXPERIMENTALSubcutaneous (SC)
Placebo IVPLACEBO_COMPARATOR -
Placebo SCPLACEBO_COMPARATOR -
Multiple Ascending Dose Placebo SCPLACEBO_COMPARATORPlacebo
Multiple Ascending Dose SCEXPERIMENTALBMS 986326 SC

Interventions

NameTypeDescription
BMS-986326DRUGSpecified dose on specified days
PlaceboOTHERSpecified dose on specified days
Placebo for BMS-986326OTHERSpecified dose on specified days
Placebo matching BMS-986326OTHERSpecified dose on specified days
Multiple Ascending Dose SCBIOLOGICALSpecified dose on specified days
Multiple Ascending Dose PlaceboOTHERSpecified dose on specified days
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites13

Inclusion Criteria: * Must have diagnosis of atopic dermatitis (AD) at least 12 months prior to screening * Documented history of inadequate response to treatment with topical medication for at least 4 weeks, unless topical treatments are otherwise medically inadvisable, or has required systemic th...

Countries:CzechiaFranceGermanyPolandSpainUnited StatesArgentinaBulgariaNetherlandsRomania
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMJun 26, 2026NCT06013995TRIAL_REMOVED: changed
MEDIUMJun 26, 2026NCT06013995TRIAL_REMOVED: changed
MEDIUMJun 26, 2026NCT06013995TRIAL_REMOVED: changed

Frequently asked questions about BMS-986326

What is BMS-986326 used for?

BMS-986326 is an investigational small molecule being studied for atopic dermatitis, lupus, and in healthy participants. It is in Phase 1 clinical development and is not yet approved by regulatory authorities.

Who makes BMS-986326?

BMS-986326 is being developed by Bristol-Myers Squibb Company, traded on the New York Stock Exchange under the ticker BMY.

What phase is BMS-986326 in?

BMS-986326 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies.

What clinical trials is BMS-986326 in?

BMS-986326 has completed three Phase 1 trials: NCT04736134 in healthy participants, NCT06013995 in adults with lupus, and NCT06248814 in participants with atopic dermatitis. All trials are completed.

Is BMS-986326 the same as any other drug?

No alternative names for BMS-986326 have been reported. It is identified solely by its compound number BMS-986326.